Overview

Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes

Status:
Terminated

Trial end date:
2012-07-01

Target enrollment:

Participant gender:

Summary

The hypothesis of this study is that 5-aza and lenalidomide act synergistically in MDS and AML patients with chromosomal abnormalities involving monosomy 5 or del5q. Therefore, this phase I study will investigate the maximum tolerated dose (MTD) of lenalidomide in combination with a fixed dose of 5-aza in this patient population.

Phase:

Phase 1

Details

Lead Sponsor:

Technische Universität Dresden

Collaborator:

Celgene Corporation

Treatments:

Azacitidine
Lenalidomide
Thalidomide